XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2022
Sep. 30, 2021
Current Assets:    
Cash and cash equivalents $ 48,044,194 $ 70,072,946
Prepaid expenses 2,790,319 2,741,404
Total Current Assets 50,834,513 72,814,350
Property and equipment, net 4,831 7,023
Operating lease right-of-use asset, net 691,593 822,828
Other Assets:    
Deposits 38,062 38,062
In-process research and development 59,400,000 59,400,000
Goodwill 9,346,796 9,346,796
Total Other Assets 68,784,858 68,784,858
Total Assets 120,315,795 142,429,059
Current Liabilities:    
Accounts payable 1,690,520 1,277,095
Accrued expenses 1,301,199 621,960
Accrued compensation 1,277,501 1,906,000
Operating lease liability 191,902 177,237
Total Current Liabilities 4,461,122 3,982,292
Deferred tax liability 4,985,800 4,985,800
Operating lease liability – noncurrent 532,883 678,234
Total Liabilities 9,979,805 9,646,326
Commitments and Contingencies
Stockholders’ Equity:    
Preferred stock – $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock – $0.001 par value; 400,000,000 shares authorized; 146,129,630 and 145,979,429 shares issued and outstanding at June 30, 2022 and September 30, 2021, respectively 146,129 145,979
Additional paid-in capital 231,287,208 228,084,195
Accumulated deficit (121,697,727) (96,047,821)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity 109,735,610 132,182,353
Non-controlling interest 600,380 600,380
Total Equity 110,335,990 132,782,733
Total Liabilities and Equity $ 120,315,795 $ 142,429,059